Where are we now? The promises and pitfalls of solid tumor CAR-T therapy
CAR T-cell therapy (CAR-T) has emerged as a therapeutic option with the ability to infiltrate and modulate the tumor microenvironment and control tumor growth....
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The treatment, policies, and study of oncology continue to undergo rapid changes and evolution, with each year bringing new opportunities and challenges for existing and new treatments. CRA positions itself on the cutting edge of the field, staying abreast of the latest issues and developments and allowing us to provide actionable, future-focused strategies for our clients.
CRA’s knowledge base stems from hundreds of engagements on solid and hematological tumors, working with clients on small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell therapies, oncology vaccines, and the increasing range of combination approaches to treating cancer.
CAR T-cell therapy (CAR-T) has emerged as a therapeutic option with the ability to infiltrate and modulate the tumor microenvironment and control tumor growth....
Late October saw the annual gathering of oncologists and industry in Madrid for ESMO 2023, bringing with it a wave of new clinical results across cancers and a...